SENS.L Regulatory News (SENS)

Sensyne Health signs agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research

Oxford, U.K. 23 October 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces it has signed a research collaboration agreement with Bristol Myers Squibb ("BMS").

Initially the collaboration will focus on applying Sensyne's proprietary machine learning to conduct research into disease progression and patient stratification for patients with various diseases within the broader group of Myeloproliferative Neoplasms ("MPNs"). MPNs comprise a group of rare blood diseases characterised by the overproduction of one or more types of blood cells - red blood cells, white blood cells and platelets. 

The collaboration will be Sensyne Health's fourth successive partnership with a major pharmaceutical company following collaborations signed with Bayer, Roche and Alexion.

No financial terms have been disclosed.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

"This new collaboration with one of the world's leading pharmaceutical companies is a further validation of Sensyne's unique model whereby Sensyne acts as the docking station between the pharmaceutical industry and providers of health data to allow for the ethical commercialisation of such data. As we continue to see wider adoption of Clinical AI and machine learning by the life sciences industry to support pharmaceutical research, Sensyne is ideally positioned to help accelerate the discovery and development of new medicines for patients."

-ENDS-

For more information please contact:

About Sensyne Health 

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com